November 2025 in “Clinical Cosmetic and Investigational Dermatology” Tofacitinib is effective and safe for treating severe alopecia areata.
Baricitinib effectively regrows hair in severe alopecia areata cases.
January 2025 in “Balkan Medical Journal” Baricitinib helps regrow hair in severe alopecia areata and is safe, but more research is needed.
September 2024 in “Journal of the Pakistan Medical Association” A 589 nm laser increases IL-2 and IFN-y gene expression in human T-cells.
April 2024 in “Journal of asthma and allergy” Abrocitinib effectively treated severe atopic dermatitis and mild alopecia areata in a 12-year-old boy after dupilumab failed.
March 2024 in “Clinical, cosmetic and investigational dermatology” Tofacitinib successfully treated vitiligo in a patient with lupus without side effects.
Upadacitinib effectively treated a patient with multiple inflammatory conditions.
3 citations
,
August 2024 in “Cureus” Upadacitinib may cause hair loss.
April 2026 in “Cellular and Molecular Immunology” SPT6 prevents excessive skin inflammation by blocking a feedback loop.
February 2026 in “Frontiers in Immunology” Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.
December 2025 in “Dermatology Reports” Topical ruxolitinib quickly improves non-segmental vitiligo.
June 2025 in “International Journal of Science and Research (IJSR)” Tofacitinib effectively promotes hair regrowth in alopecia areata with minimal side effects.
March 2024 in “Clinical, cosmetic and investigational dermatology” Upadacitinib may effectively treat alopecia areata without side effects.
January 2021 in “Research Square (Research Square)” Rabbits with high wool production have more hair follicles, influenced by specific long noncoding RNAs.
September 2020 in “Research Square (Research Square)” Long noncoding RNAs help regulate hair follicle density in rabbits.
January 2016 in “Chemistry & Industry” Two drugs, tofacitinib and ruxolitinib, may help regrow hair by activating hair follicles.
September 2024 in “Drugs & Therapy Perspectives” Ritlecitinib effectively regrows hair in severe alopecia areata and is well tolerated.
54 citations
,
February 1993 in “Endocrine reviews” Androgen conjugates might be better indicators of skin sensitivity to hormones in women with excessive hair growth.
49 citations
,
August 2018 in “International Journal of Dermatology” Topical JAK inhibitors may help treat alopecia universalis by promoting hair regrowth.
34 citations
,
July 2010 in “Expert Opinion on Drug Delivery” The document concludes that there is no agreed-upon best method for measuring drug delivery within hair follicles and more research is needed to validate current techniques.
27 citations
,
November 2021 in “Scientific Reports” Men are more affected by COVID-19 due to differences in immune responses and protein expression.
27 citations
,
July 2017 in “European Journal of Dermatology” Certain microRNAs are linked to various skin diseases and could be used to diagnose and treat these conditions.
20 citations
,
January 2017 in “Actas Dermo-Sifiliográficas” Recent advances in hair loss treatments show significant progress.
11 citations
,
December 2018 in “Journal of the European Academy of Dermatology and Venereology” Stopping JAK inhibitor treatment for hair loss can lead to worse hair loss than before the treatment.
8 citations
,
June 2024 in “APOPTOSIS” Caspases affect many cell functions and could help treat various diseases.
7 citations
,
March 2017 in “Actas Dermo-Sifiliográficas” Several new treatments for different types of hair loss show promise in improving patient quality of life.
6 citations
,
September 2025 in “Scientific Reports” Machine learning can accurately diagnose PCOS non-invasively using clinical and ultrasound features.
2 citations
,
June 2020 in “AIDS” Recreational drug use can cause misdiagnosed conditions and drug interactions in HIV patients.
1 citations
,
January 2023 in “Research Square (Research Square)” A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.
July 2024 in “Medical alphabet” Combining treatments is key to managing vitiligo effectively.